6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
labeling O
: O
* O
Hypocalcemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Upper B-OSE_Labeled_AE
Gastrointestinal I-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hypotension B-OSE_Labeled_AE
, O
Worsening B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
and/or O
Arrhythmias B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Adynamic B-OSE_Labeled_AE
Bone I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
i.e. O
, O
> O
= O
25 O
% O
) O
associated O
with O
Sensipar O
were O
nausea O
and O
vomiting O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Medical O
Information O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Secondary O
Hyperparathyroidism O
in O
Patients O
with O
Chronic O
Kidney O
Disease O
on O
Dialysis O
In O
three O
double-blind O
, O
placebo-controlled O
clinical O
trials O
, O
1126 O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
received O
study O
drug O
( O
656 O
Sensipar O
, O
470 O
placebo O
) O
for O
up O
to O
6 O
months O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
are O
listed O
in O
Table O
1 O
. O

Seizures B-OSE_Labeled_AE
were O
observed O
in O
1.4 O
% O
( O
13/910 O
) O
of O
Sensipar-treated O
patients O
and O
0.7 O
% O
( O
5/641 O
) O
of O
placebo-treated O
patients O
across O
all O
completed O
placebo O
controlled O
trials O
. O

Table O
1 O
. O

Adverse O
Reactions O
with O
Frequency O
> O
= O
5 O
% O
in O
Patients O
on O
Dialysis O
in O
Short-Term O
Studies O
for O
up O
to O
6 O
Months O
Placebo O
Sensipar O
( O
n O
= O
470 O
) O
( O
n O
= O
656 O
) O
Event* O
: O
( O
% O
) O
( O
% O
) O
Nausea B-OSE_Labeled_AE
19 O
31 O
Vomiting B-OSE_Labeled_AE
15 O
27 O
Diarrhea B-OSE_Labeled_AE
20 O
21 O
Myalgia B-OSE_Labeled_AE
14 O
15 O
Dizziness B-OSE_Labeled_AE
8 O
10 O
Hypertension B-OSE_Labeled_AE
5 O
7 O
Asthenia B-OSE_Labeled_AE
4 O
7 O
Anorexia B-OSE_Labeled_AE
4 O
6 O
Pain B-OSE_Labeled_AE
Chest I-OSE_Labeled_AE
, I-OSE_Labeled_AE
Non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cardiac I-OSE_Labeled_AE
4 O
6 O
Dialysis B-OSE_Labeled_AE
Access I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
4 O
5 O
*Included O
are O
events O
that O
were O
reported O
at O
a O
greater O
incidence O
in O
the O
Sensipar O
group O
than O
in O
the O
placebo O
group O
. O

In O
a O
randomized O
, O
double-blind O
placebo O
controlled O
study O
of O
3883 O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
receiving O
dialysis O
in O
which O
patients O
were O
treated O
for O
up O
to O
64 O
months O
( O
mean O
duration O
of O
treatment O
was O
21 O
months O
in O
the O
Sensipar O
group O
) O
, O
the O
most O
frequently O
reported O
adverse O
reactions O
( O
incidence O
of O
> O
= O
5 O
% O
in O
the O
Sensipar O
group O
and O
a O
difference O
> O
= O
1 O
% O
compared O
to O
placebo O
) O
are O
listed O
in O
Table O
2 O
. O

Table O
2 O
. O

Frequency O
of O
Adverse O
Reactions O
in O
Dialysis O
Patients O
Treated O
for O
up O
to O
64 O
Months O
in O
a O
Long-Term O
Study1 O
Placebo O
( O
n O
= O
1923 O
) O
Sensipar O
( O
n O
= O
1938 O
) O
3699 O
subject-years O
4044 O
subject-years O
Percent O
of O
subjects O
reporting O
Adverse O
Reactions O
( O
% O
) O
90.9 O
93.2 O
Nausea B-OSE_Labeled_AE
15.5 O
29.1 O
Vomiting B-OSE_Labeled_AE
13.7 O
25.6 O
Diarrhea B-OSE_Labeled_AE
18.7 O
20.5 O
Dyspnea B-OSE_Labeled_AE
11.5 O
13.4 O
Cough B-OSE_Labeled_AE
9.8 O
11.7 O
Hypotension B-OSE_Labeled_AE
10.5 O
11.6 O
Headache B-OSE_Labeled_AE
9.6 O
11.5 O
Hypocalcemia B-OSE_Labeled_AE
1.4 O
11.2 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
9.2 O
11.1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
9.6 O
10.9 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
6.3 O
8.2 O
Hyperkalemia B-OSE_Labeled_AE
6.1 O
8.1 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6.3 O
7.6 O
Dyspepsia B-OSE_Labeled_AE
4.6 O
7.4 O
Dizziness B-OSE_Labeled_AE
4.7 O
7.3 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
3.5 O
5.9 O
Asthenia B-OSE_Labeled_AE
3.8 O
5.4 O
Constipation B-OSE_Labeled_AE
3.8 O
5.0 O
1 O
Adverse O
reactions O
that O
occurred O
in O
> O
= O
5 O
% O
frequency O
in O
the O
Sensipar O
group O
and O
a O
difference O
> O
= O
1 O
% O
compared O
to O
the O
placebo O
group O
( O
Safety O
Analysis O
Set O
) O
Crude O
incidence O
rate O
= O
100 O
* O
Total O
number O
of O
subjects O
with O
event/ O
n O
n O
= O
Number O
of O
subjects O
receiving O
at O
least O
one O
dose O
of O
study O
drug O
Additional O
adverse O
reaction O
rates O
from O
the O
long-term O
, O
randomized O
, O
double-blind O
placebo O
controlled O
study O
for O
Sensipar O
versus O
placebo O
are O
as O
follows O
: O
seizure B-OSE_Labeled_AE
( O
2.5 O
% O
, O
1.6 O
% O
) O
, O
rash B-OSE_Labeled_AE
( O
2.2 O
% O
, O
1.9 O
% O
) O
, O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
9.4 O
% O
, O
8.3 O
% O
) O
. O

Patients O
with O
Parathyroid O
Carcinoma O
and O
Primary O
Hyperparathyroidism O
The O
safety O
profile O
of O
Sensipar O
in O
these O
patient O
populations O
is O
generally O
consistent O
with O
that O
seen O
in O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
. O

Forty O
six O
patients O
were O
treated O
with O
Sensipar O
in O
a O
single O
arm O
study O
, O
29 O
with O
Parathyroid B-Not_AE_Candidate
Carcinoma I-Not_AE_Candidate
and O
17 O
with O
intractable O
pHPT B-Not_AE_Candidate
. O

Nine O
( O
20 O
% O
) O
of O
the O
patients O
withdrew O
from O
the O
study O
due O
to O
adverse O
events O
. O

The O
most O
frequent O
adverse O
reactions O
and O
the O
most O
frequent O
cause O
of O
withdrawal O
in O
these O
patient O
populations O
were O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
. O

Severe O
or O
prolonged O
cases O
of O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
can O
lead O
to O
dehydration B-NonOSE_AE
and O
worsening O
hypercalcemia B-NonOSE_AE
so O
careful O
monitoring O
of O
electrolytes O
is O
recommended O
in O
patients O
with O
these O
symptoms O
. O

Eight O
patients O
died O
during O
treatment O
with O
Sensipar O
in O
this O
study O
, O
7 O
with O
Parathyroid B-Not_AE_Candidate
Carcinoma I-Not_AE_Candidate
( O
24 O
% O
) O
and O
1 O
( O
6 O
% O
) O
with O
intractable O
pHPT B-Not_AE_Candidate
. O

Causes O
of O
death B-NonOSE_AE
were O
cardiovascular B-NonOSE_AE
( O
5 O
patients O
) O
, O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
( O
1 O
patient O
) O
, O
gastrointestinal B-NonOSE_AE
hemorrhage I-NonOSE_AE
( O
1 O
patient O
) O
and O
metastatic B-NonOSE_AE
carcinoma I-NonOSE_AE
( O
1 O
patient O
) O
. O

Adverse O
events O
of O
hypocalcemia B-OSE_Labeled_AE
were O
reported O
in O
three O
patients O
( O
7 O
% O
) O
. O

Seizures B-OSE_Labeled_AE
were O
observed O
in O
0.7 O
% O
( O
1/140 O
) O
of O
cinacalcet-treated O
patients O
and O
0.0 O
% O
( O
0/46 O
) O
of O
placebo-treated O
patients O
in O
all O
clinical O
studies O
. O

Table O
3 O
. O

Adverse O
Reactions O
with O
Frequency O
> O
= O
10 O
% O
in O
a O
Single O
Arm O
, O
Open-Label O
Study O
in O
Patients O
with O
Primary O
Hyperparathyroidism O
or O
Parathyroid O
Carcinoma O
Sensipar O
ParathyroidCarcinoma O
( O
n O
= O
29 O
) O
IntractablepHPT O
( O
n O
= O
17 O
) O
Total O
( O
n O
= O
46 O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
Number O
of O
Subjects O
Reporting O
Adverse O
Reactions O
28 O
( O
97 O
) O
17 O
( O
100 O
) O
45 O
( O
98 O
) O
Nausea B-OSE_Labeled_AE
19 O
( O
66 O
) O
10 O
( O
59 O
) O
29 O
( O
63 O
) O
Vomiting B-OSE_Labeled_AE
15 O
( O
52 O
) O
6 O
( O
35 O
) O
21 O
( O
46 O
) O
Paresthesia B-OSE_Labeled_AE
4 O
( O
14 O
) O
5 O
( O
29 O
) O
9 O
( O
20 O
) O
Fatigue B-OSE_Labeled_AE
6 O
( O
21 O
) O
2 O
( O
12 O
) O
8 O
( O
17 O
) O
Fracture B-OSE_Labeled_AE
6 O
( O
21 O
) O
2 O
( O
12 O
) O
8 O
( O
17 O
) O
Hypercalcemia B-OSE_Labeled_AE
6 O
( O
21 O
) O
2 O
( O
12 O
) O
8 O
( O
17 O
) O
Anorexia B-OSE_Labeled_AE
6 O
( O
21 O
) O
1 O
( O
6 O
) O
7 O
( O
15 O
) O
Asthenia B-OSE_Labeled_AE
5 O
( O
17 O
) O
2 O
( O
12 O
) O
7 O
( O
15 O
) O
Dehydration B-OSE_Labeled_AE
7 O
( O
24 O
) O
0 O
( O
0 O
) O
7 O
( O
15 O
) O
Anemia B-OSE_Labeled_AE
5 O
( O
17 O
) O
1 O
( O
6 O
) O
6 O
( O
13 O
) O
Arthralgia B-OSE_Labeled_AE
5 O
( O
17 O
) O
1 O
( O
6 O
) O
6 O
( O
13 O
) O
Constipation B-OSE_Labeled_AE
3 O
( O
10 O
) O
3 O
( O
18 O
) O
6 O
( O
13 O
) O
Depression B-OSE_Labeled_AE
3 O
( O
10 O
) O
3 O
( O
18 O
) O
6 O
( O
13 O
) O
Headache B-OSE_Labeled_AE
6 O
( O
21 O
) O
0 O
( O
0 O
) O
6 O
( O
13 O
) O
Infection B-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
3 O
( O
10 O
) O
2 O
( O
12 O
) O
5 O
( O
11 O
) O
Pain B-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
3 O
( O
10 O
) O
2 O
( O
12 O
) O
5 O
( O
11 O
) O
n O
= O
Number O
of O
subjects O
receiving O
at O
least O
one O
dose O
of O
study O
drug O
. O

pHPT B-Not_AE_Candidate
= I-Not_AE_Candidate
primary I-Not_AE_Candidate
hyperparathyroidism I-Not_AE_Candidate
In O
a O
randomized O
double-blind O
, O
placebo-controlled O
study O
of O
67 O
patients O
with O
primary B-Not_AE_Candidate
hyperparathyroidism I-Not_AE_Candidate
for O
whom O
parathyroidectomy O
would O
be O
indicated O
on O
the O
basis O
of O
serum O
calcium O
levels O
, O
but O
who O
are O
unable O
to O
undergo O
surgery O
, O
the O
most O
common O
adverse O
reactions O
are O
listed O
in O
Table O
4 O
. O

Table O
4 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
= O
10 O
% O
of O
Subjects O
in O
a O
Double-Blind O
, O
Placebo-Controlled O
Study O
in O
Patients O
with O
Primary O
Hyperparathyroidism O
Adverse O
Reaction O
Placebo O
( O
n O
= O
34 O
) O
n O
( O
% O
) O
Cinacalcet O
( O
n O
= O
33 O
) O
n O
( O
% O
) O
Nausea B-OSE_Labeled_AE
6 O
( O
18 O
) O
10 O
( O
30 O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
0 O
( O
0 O
) O
6 O
( O
18 O
) O
Headache B-OSE_Labeled_AE
2 O
( O
6 O
) O
4 O
( O
12 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
( O
6 O
) O
4 O
( O
12 O
) O
n O
= O
Number O
of O
subjects O
receiving O
at O
least O
one O
dose O
of O
study O
drug O
Coded O
using O
MedDRA O
version O
16.0 O
Hypocalcemia O
In O
26-week O
studies O
of O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
on O
dialysis O
66 O
% O
of O
patients O
receiving O
Sensipar O
compared O
with O
25 O
% O
of O
patients O
receiving O
placebo O
developed O
at O
least O
one O
serum O
calcium O
value O
less O
than O
8.4 O
mg/dL O
, O
whereas O
, O
29 O
% O
of O
patients O
receiving O
Sensipar O
compared O
with O
11 O
% O
of O
patients O
receiving O
placebo O
developed O
at O
least O
one O
serum O
calcium O
value O
less O
than O
7.5 O
mg/dL O
. O

Less O
than O
1 O
% O
of O
patients O
in O
each O
group O
permanently O
discontinued O
study O
drug O
due O
to O
hypocalcemia B-OSE_Labeled_AE
. O

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
receiving O
dialysis O
in O
which O
patients O
were O
treated O
for O
up O
to O
64 O
months O
( O
mean O
duration O
of O
treatment O
was O
21 O
months O
in O
the O
cinacalcet O
group O
) O
, O
75 O
% O
of O
patients O
receiving O
Sensipar O
compared O
with O
29 O
% O
of O
patients O
receiving O
placebo O
developed O
at O
least O
one O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
value I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
and O
33 O
% O
of O
cinacalcet O
patients O
compared O
with O
12 O
% O
of O
patients O
receiving O
placebo O
had O
at O
least O
one O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
value I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
. O

Most O
of O
the O
cases O
of O
severe O
hypocalcemia B-OSE_Labeled_AE
less O
than O
7.5 O
mg/dL O
( O
21/33=64 O
% O
) O
occurred O
during O
the O
first O
6 O
months O
. O

In O
this O
trial O
, O
1.1 O
% O
of O
patients O
receiving O
Sensipar O
and O
0.1 O
% O
of O
patients O
receiving O
placebo O
permanently O
discontinued O
study O
drug O
due O
to O
hypocalcemia B-OSE_Labeled_AE
. O

During O
a O
placebo-controlled O
part O
of O
a O
52-week O
study O
in O
patients O
with O
primary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
who O
met O
criteria O
for O
parathyroidectomy O
on O
the O
basis O
of O
corrected O
total O
serum O
calcium O
( O
> O
11.3 O
mg/dL O
[ O
2.82 O
mmol/L O
] O
and O
< O
= O
12.5 O
mg/dL O
[ O
3.12 O
mmol/L O
] O
) O
, O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
observed O
in O
6.1 O
% O
( O
2/33 O
) O
of O
Sensipar O
treated O
patients O
and O
0 O
% O
( O
0/34 O
) O
of O
placebo O
treated O
patients O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
Sensipar O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Rash B-OSE_Labeled_AE
and O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
angioedema B-OSE_Labeled_AE
and O
urticaria B-OSE_Labeled_AE
) O
, O
and O
myalgia B-OSE_Labeled_AE
* O
Isolated O
, O
idiosyncratic O
cases O
of O
hypotension B-OSE_Labeled_AE
, O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and/or O
arrhythmia B-OSE_Labeled_AE
have O
been O
* O
reported O
in O
patients O
with O
impaired B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
function I-Not_AE_Candidate
* O
Gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE

